Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer.

The Journal of clinical investigation·2026
Same author

Comparison of [<sup>18</sup>F]DCFPyL and [<sup>18</sup>F]FAPI-74 PET/CT imaging in metastatic prostate cancer.

European journal of nuclear medicine and molecular imaging·2026
Same author

MRI-targeted versus systematic needle core biopsies in prostate cancer: a patient-based analysis of potential diagnostic and biologic underestimation.

Journal of clinical pathology·2026
Same author

Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer.

Neoplasia (New York, N.Y.)·2026
Same author

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer.

Molecular cancer research : MCR·2026
Same author

HLA Class I Expression is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer.

Molecular cancer research : MCR·2026
Same journal

Dietary phytoestrogen intake and risk of receptor-defined breast cancer subtypes: a prospective analysis of the PLCO Cancer Screening Trial cohort.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Disparities in Rural-Urban Cancer Care Outcomes Among Pediatric, Adolescent, and Young Adult Populations: A Comprehensive Narrative Review.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Patterns of Multimorbidity among Older Adults with Colorectal Cancer Living in Puerto Rico.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

The Food and Microbiome Longitudinal Investigation (FAMiLI) Study: an Asian American (AsA) Enriched Multi-ethnic Environmental Cohort.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

Plasma protein biomarkers for early risk prediction of colorectal cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same journal

No association of prior administration of selected vaccines with lymphoma prognosis.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
See all related articles

Related Experiment Video

Updated: Oct 4, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource.

Véronique Ouellet1, Andrew Erickson2,3,4,

  • 1Centre de recherche du Centre hospitalier de l'Université de Montréal et Institut du cancer de Montréal, Montreal, Canada.

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
|February 8, 2022
PubMed
Summary
This summary is machine-generated.

Researchers created unique prostate cancer tissue microarrays (TMA) to understand diverse patient outcomes. This Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) resource aids biomarker validation for improved treatment strategies.

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

815
Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
05:49

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Published on: October 10, 2019

6.7K

Related Experiment Videos

Last Updated: Oct 4, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

815
Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
05:49

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Published on: October 10, 2019

6.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Prostate cancer outcomes vary significantly, necessitating research into molecular underpinnings.
  • Understanding this heterogeneity is a key priority for Movember.
  • The Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project was initiated to address this challenge.

Purpose of the Study:

  • To construct and provide a comprehensive resource of annotated prostate cancer tissue microarrays (TMA).
  • To facilitate biomarker validation for predicting disease progression and treatment response.
  • To investigate molecular differences in primary tumors, lymph node metastases, and castration-resistant prostate cancer (CRPC).

Main Methods:

  • Development of three distinct TMA sets (TMA1, TMA2, TMA3) from prostate cancer samples.
  • Collection of samples from multiple global institutions.
  • Rich clinical annotation of all tissue specimens.

Main Results:

  • Successful creation of the GAP1-UTMA project, comprising tissue specimens from 501 prostate cancer patients.
  • Detailed characterization of TMA1 for validating biomarkers related to lymph node metastasis and progression.
  • TMA2 designed to study castration-resistant prostate cancer (CRPC) and response to androgen deprivation therapy (ADT).
  • TMA3 established to assess molecular marker heterogeneity in lethal prostate cancer metastases across different anatomical sites.

Conclusions:

  • The GAP1-UTMA project has generated a valuable, well-annotated resource for the prostate cancer research community.
  • This resource is available for biomarker validation to address critical clinical questions.
  • It will aid in understanding disease progression and optimizing treatment strategies.